Predicting West Nile Virus risk across Europe for the current and future conditions

Withers, A. J.; Croft, S.; Budgey, R.; Warren, D. A.; Johnson, N.

doi:10.1101/2025.03.04.640552

Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.03.04.640552

Predicting West Nile Virus risk across Europe for the current and future conditions

Withers, A. J.·Croft, S.·Budgey, R.·Warren, D. A.·Johnson, N.

View original source ↗Export metadata ↓

Abstract

Vector-borne diseases have significant impacts on animal and human health globally, and these impacts are likely to increase in the future due to environmental and climate change. Understanding where to target surveillance and control measures to mitigate the impacts of emerging vector-borne diseases can be challenging when pathogens or disease is absent. In this study, we utilise a species distribution modelling approach previously applied to the UK to predict areas at higher risk of mosquito-borne disease across Europe, using West Nile Virus (WNV) as a case study. WNV is an Orthoflavivirus that is naturally transmitted between Culex mosquitoes and a range of avian species. However, it can spread to hosts such as humans and horses where it has the potential to lead to severe illness and mortality. Suitability predictions for Culex (Cx. pipiens and Cx. modestus) and avian hosts (mainly Passerine species) are made across Europe to determine potential risk of WNV circulation and establishment. These maps are then combined with information on human and horse density to determine risk to human and equine health. The resulting risk maps reveal that across Europe, there are areas of higher and lower risk that are predominantly driven by vector suitability as avian hosts are widespread. These predictions are projected into the future in 2100 using best- and worst-case Shared Socioeconomic Pathways (SSP1 and SSP5 respectively) to determine how risk may change over time, revealing that some areas see an increase in suitability for both vectors and hosts leading to higher risk (e.g., central England and northern Belgium) whilst other areas see a decline in suitability and consequently lower WNV risk (e.g., northern Italy and western Germany). Overall, this work will improve understanding of mosquito-borne disease risk in changing environments and demonstrates how species distribution modelling can be used to aid contingency preparedness by highlighting areas at higher risk of emerging disease.

Explore related subjects

pathology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Withers, A. J., Croft, S., Budgey, R., Warren, D. A., Johnson, N.. 2025-03-10. Predicting West Nile Virus risk across Europe for the current and future conditions. https://doi.org/10.1101/2025.03.04.640552

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Negative association between nodular stromal fibrosis and large lipid droplets in human choroid plexus epithelial cells

Fibrosis is an age-related change within the human choroid plexus that is likely to affect its function negatively. We systematically analyzed nodular stromal fibrosis present in postmortem tissue from a large repository encompassing the human lifespan. Following manual annotation of sampled images from 81 specimens of choroid plexus from the atrium of the lateral ventricle, a deep learning model was trained to assess stages of fibrosis (dense, hyalinized, and mineralized) occurring in papillae across whole slide images of hematoxylin and eosin-stained sections from 204 cases. The percentage of affected papillae and the relative area of fibrosis at all three stages of severity increased with age. Affected papillae were significantly clustered across the choroid plexus, with areas of high and low fibrotic density. Choroid plexus epithelial cells (CPECs) associated with fibrotic papillae were less likely to contain large lipid droplets than were non-fibrotic papillae, as assessed by another deep learning model. Across papillae within a case, the area of each stage of fibrosis was negatively correlated with the prevalence of CPECs containing large lipid droplets. Finally, individuals displaying more nodular fibrosis had significantly fewer CPECs containing large lipid droplets. Thus, age-related nodular stromal fibrosis may negatively impact lipid storage and homeostasis for the choroid plexus and brain.

pathology↗

bioRxiv2026

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

bioRxiv2026

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗